Our present studies demonstrated that in MCL cells, G-1 down-regulated the NF-κB pathway by decreasing the phosphorylation of p65 and G-1 and ibrutinib exhibited a synergistic effect on inhibiting proliferation in MCL cell lines, providing a possible treatment strategy for ibrutinib-resistant MCL patients. The gene discussed is NFKB1; the disease is mantle cell lymphoma.